BrightInsight vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
BrightInsight is the leading global regulated digital health platform for biopharma and medtech; raised $166M total (Series C $101M led by General Catalyst in 2021); supports SaMD, connected devices, and disease management programs.
About
BrightInsight is a digital health infrastructure company that provides the leading global regulated platform for biopharma and medtech companies building Software as a Medical Device (SaMD) and connected health programs. Founded in 2017 by Kal Patel, a former Bristol-Myers Squibb executive, BrightInsight is headquartered in San Jose, California. The company's platform captures, transmits, and analyzes data from FDA-regulated and CE-marked medical devices, combination products, digital therapeutics, and companion apps — all while maintaining compliance with HITRUST, GDPR, FDA 21 CFR Part 11, IEC 62304, and other regulatory frameworks. This regulated-by-design infrastructure layer eliminates the need for biopharma and medtech companies to build compliant digital health backends from scratch.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies;
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.